INSP Inspire Medical Systems, Inc. Insider Trading

Director Curet nets 1-share sale across 4 transactions (mixed buys and sells); currently $117.29 vs 52-week high of $215.42.

Curet Myriam executed 4 separate transactions over five months: 2 purchases totaling 5 shares for $803.62 and 2 sales totaling 6 shares for $615.55, resulting in a net 1-share sale. The buying occurred at $163.84 and $148.26 (March and April), while the selling occurred at much lower prices of $153.22 and $77.28 (May and August). This price progression—with the August sale at $77.28 representing a 53% decline from the March purchase price of $163.84—suggests the director was selling at depressed valuations. Currently at $117.29, the stock has recovered from the August lows but remains 45.6% below its 52-week high of $215.42. The director's post-transaction holdings of 3,365 shares represent minimal portfolio impact (net change of -1 share), making this a marginal activity that does not materially alter her director-level position.

CFO Buchholz sold 11,000 INSP shares at $93.39; stock down 56.4% from 52-week high, he's now down to 44,867 shares held

Buchholz sold 11,000 shares at $93.39, reducing his position by 19.7% to 44,867 shares post-transaction. The timing is notable: his prior sell at INSP on 2024-04-17 posted a 90-day return of -36.6%, representing a well-timed exit, and this new sale occurs as the stock has fallen 25.0% over the last 30 days and 31.5% over 90 days from elevated levels ($216.71 52-week high). Current price of $94.51 sits 56.4% below that high, suggesting material deterioration in valuation since peak. The company posted net income of $-3,592,000.00 in the latest quarter despite revenue growth of 28.5% year-over-year, indicating profitability challenges beneath top-line expansion. The prior INSP transaction's favorable timing pattern—where the stock subsequently declined—provides historical context for evaluating whether the insider again anticipated downside.

Ban Randy sells 25,584 shares of INSP for $4.7M across 10 transactions on 2025-02-13, reducing holdings by 77.9%

Ban Randy executed 10 separate sales totaling 25,584 shares for $4,694,765.58, reducing his stake from 32.8K shares to 7.3K shares (a -77.9% reduction). The sales occurred across a narrow price band ($178.54–$187.66) at a blended average price of $183.50, trading against a current price of $180.08 and a 52-week high of $251.19. His prior 5 sales at INSP all showed negative 90-day returns (ranging from -5.1% to -8.8%), meeting his pattern of well-timed exits at this ticker. The scale and structure of this filing—a nearly complete liquidation across multiple tranches in a single day—stands out against his holdings and warrant investor scrutiny regarding confidence in the company's near-term trajectory.

CTO Rondoni John sold 8,703 shares for $1,683,730.99, reducing INSP holdings by 43.4% to 11,348 shares

Rondoni John, Chief Technology Officer at Inspire Medical Systems (INSP), executed 4 separate sales totaling 8,703 shares for $1,683,730.99 at a blended average price of $193.47 on 2024-11-01, cutting his holdings nearly in half from 20,051 to 11,348 shares. His prior trades at INSP demonstrate a strong timing pattern: of 5 prior same-ticker sales (3 in March, 2 in August 2024), all 3 with measurable 90-day outcomes showed negative post-sale returns, indicating well-timed exits ahead of declines. The current stock price of $199.00 reflects a -7.4% decline over the prior 30 days and sits -20.8% from its 52-week high of $251.19, suggesting the downward trend was underway at sale. While INSP shows strong fundamentals (revenue growth of +53.2%, net income of $18,497,000.00), the stock carries a historically elevated P/E of 180.91, and the company was unprofitable over its most recent full fiscal year despite recent quarterly profitability—conditions that may explain why a C-level executive with a pattern of well-timed sells chose to substantially reduce exposure.

Inspire Medical CTO John Rondoni sells 5,000 INSP shares for $949.1K in 2 separate transactions at $189.16–$190.04

John Rondoni, CTO of Inspire Medical Systems (INSP), executed 2 separate sales totaling 5,000 shares for $949,143.12, reducing his holdings from 16,379 to 11,379 shares (a 30.5% reduction). The stock trades at $191.48 today, near the transaction prices of $189.16 and $190.04. Notably, Rondoni's prior 5 sales at INSP occurred in February and March 2024, all of which were well-timed at the 90-day mark (each followed by negative 90d returns ranging from -10.5% to -14.1%), and his cross-ticker track record shows a 100.00% well-timed rate across 7 prior sells. The company trades at a P/E of 957.40 with elevated valuation metrics (market cap $5.7B), though it demonstrated strong recent revenue growth of +53.2% and posted $9.8M net income last quarter. The continued insider selling pattern after months of prior exits, combined with a consistently demonstrated ability to exit before subsequent declines, warrants investor attention alongside the stock's current proximity to its 52-week high of $251.19.

CCO Ban Randy sold 21,000 shares ($4.0M) over 2 days at avg $192.05; holdings cut 87.3% to 3.1K shares.

Ban Randy, Chief Commercial Officer at Inspire Medical Systems, executed 9 separate sales over August 15–16, 2024, totaling 21,000 shares for $4,032,945.90 at a blended average price of $192.05. This represents a -87.3% reduction in his holdings, leaving only 3.1K shares post-transaction. The multi-day execution across price points ranging from $187.10 to $194.91 suggests a planned liquidation rather than a reactive single-date sale. Ban Randy's prior trading activity at INSP shows a 2 of 2 pattern of well-timed sells (both prior trades posted negative 90-day returns of -12.8% and -16.5%), though his cross-ticker track record has produced only a 12.2% average 30-day return against a -14.6% average 90-day return. The company's fundamentals present a disconnect: while annual revenue growth reached +53.2% and the latest quarterly revenue totaled $195,885,000.00, the company remains unprofitable on a full-year basis and carries an elevated P/E of 970.15. The stock is currently -22.8% from its 52-week high of $251.19 despite a +35.0% 30-day rally, leaving investors to assess whether the CCO's substantial share liquidation reflects confidence in near-term momentum or prudent reduction of concentrated exposure.